Physician profile
Ryan C Coy
NPI 1821525890
$2,638.03
in general payments reported to CMS, 2019-2025
16 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 88% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $439 · 2023: $386 · 2024: $768 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.65 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Globus Medical, INC. | $617.38 | 2025 | Senza |
| Nevro Corp. | $390.85 | 2022-2024 | Senza |
| Boston Scientific Corporation | $182.38 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Si-Bone, INC. | $147.66 | 2024 | |
| Stryker Corporation | $110.92 | 2025 | Mild Device Kit |
| Abbott Laboratories | $76.42 | 2023-2024 | Proclaim |
| Pfizer INC. | $35.00 | 2025 | |
| Medtronic, INC. | $18.16 | 2022 | |
| Bioventus LLC | $16.75 | 2025 | Durolane |
| Lilly USA, LLC | $16.15 | 2023 | Emgality, Reyvow |
| Merz Pharmaceuticals, LLC | $15.99 | 2024 | Xeomin |
| Allergan, INC. | $15.45 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.75 | 2025 | |
| Depuy Synthes Sales INC. | $14.34 | 2023 | Monovisc, Orthovisc |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Coy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.